{
    "clinical_study": {
        "@rank": "132622", 
        "acronym": "Morpheus PK", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the current trial is to evaluate the bioavailability of a single oral dose of\n      naproxen sodium 440 mg and DPH HCL 50 mg under fasting and fed conditions and currently\n      marketed single ingredient products containing naproxen sodium (2 x Aleve\u00ae 220 mg tablets)\n      or DPH HCL (2 Allergy Relief x 25 mg tablets) under fasting conditions."
        }, 
        "brief_title": "Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Therapeutic Equivalence", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Health, ambulatory male and female subjects between 18 to 55 years of age inclusive\n\n          -  Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg\n             (110 lbs)\n\n          -  Results of screening and clinical laboratory tests are within normal range or\n             considered not clinically significant by the Principal Investigator or Sponsor\n\n          -  Female subjects of childbearing potential must be using a medically acceptable form\n             of birth control for at least 1 month prior to screening (3 months on oral\n             contraceptives), e.g., oral or patch contraceptives, intrauterine device,\n             Depo-Provera, or a double barrier and have a negative pregnancy test at Screening and\n             Day 0 for each Dosing Period.  Female subjects of non childbearing potential must be\n             amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity to aspirin (ASA), naproxen sodium, NSAIDs, acetaminophen,\n             DPH HCL, and similar pharmacological agents or components of the products\n\n          -  History of hypersensitivity to any of the food products in the standardized breakfast\n             or cannot consume all food/beverage items contained in the standardized breakfast\n\n          -  Have taken ASA, ASA-containing products, acetaminophen or any other NSAID (OTC or\n             prescription) 7 days prior to dosing or during the Dosing Periods, other than trial\n             treatment\n\n          -  Use of any over-the-counter or prescription medications (except acceptable forms of\n             birth control) within 10 days prior to dosing or throughout the trial, unless in the\n             opinion of the Investigator, the medication will not interfere with the trial\n             procedures, data integrity, or compromise the safety of the subject\n\n          -  Recently had (past 30 days) or plan to have surgery, an invasive procedure, tattoos\n             or piercings during the trial or 1-2 weeks after treatment\n\n          -  Loss of blood in excess of 500 ml within 56 days of the first dose of trial treatment\n             (e.g., donation, plasmapheresis or injury)\n\n          -  History of gastrointestinal bleeding or perforation, related to previous NSAID\n             therapy or  active or history of recurrent peptic ulcer/hemorrhage (two or more\n             distinct episodes of proven ulceration or bleeding)\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic\n             diseases or malignancies\n\n          -  Smokers or currently consuming any type of tobacco product(s) including any smoking\n             cessation nicotine-containing product (e.g., nicotine patch, nicotine gum)\n\n          -  Have taken any vitamin or herbal supplement within 7 days prior to dosing or refuse\n             to refrain from use during the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01666678", 
            "org_study_id": "16135"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions", 
                "intervention_name": "BAY98-7111", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "2 x Naproxen Sodium 220 mg under fasting conditions", 
                "intervention_name": "Naproxen Sodium (Aleve, BAYH6689)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "description": "2 x Diphenhydramine HCl 25 mg under fasting conditions", 
                "intervention_name": "Diphenhydramine HCl", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "description": "2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions", 
                "intervention_name": "BAY98-7111", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naproxen", 
                "Diphenhydramine", 
                "Promethazine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Bioequivalence", 
        "lastchanged_date": "August 8, 2013", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Hackensack", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07601"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Bioavailability Study of Naproxen Sodium and Diphenhydramine Hydrochloride Under Fasting Conditions and Naproxen Sodium and Diphenhydramine Hydrochloride Combination Under Fasting and Fed Conditions", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC(0-tn) (area under the measurement versus time curve from time 0 to the last data point) of naproxen sodium", 
                "safety_issue": "No", 
                "time_frame": "within 30 minutes prior to dosing (baseline) and 10, 20, 30, 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, and 36 hours post dosing"
            }, 
            {
                "measure": "AUC(0-tn) (area under the measurement versus time curve from time 0 to the last data point) of DPH HCL(Diphenhydramine Hydrochloride)", 
                "safety_issue": "No", 
                "time_frame": "within 30 minutes prior to dosing (baseline) and 10, 20, 30, 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, and 36 hours post dosing"
            }, 
            {
                "measure": "Cmax(Maximum drug concentration) in plasma of naproxen sodium", 
                "safety_issue": "No", 
                "time_frame": "within 30 minutes prior to dosing (baseline) and 10, 20, 30, 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, and 36 hours post dosing"
            }, 
            {
                "measure": "Cmax(Maximum drug concentration) in plasma of DPH HCL(Diphenhydramine Hydrochloride)", 
                "safety_issue": "No", 
                "time_frame": "within 30 minutes prior to dosing (baseline) and 10, 20, 30, 45 minutes and 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 12, 24, and 36 hours post dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01666678"
        }, 
        "responsible_party": {
            "name_title": "Head Clinical and Medical Affairs", 
            "organization": "Bayer Consumer Care L.L.C."
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 6 weeks"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}